Felix Rausch

Cardiologist in Training, UMC Mainz || Clinician scientist with special interest in #heartfailure and #cardioimmunology

[NEJM @NEJM]

Neutralizing interleukin-10 autoantibodies were found in a subgroup of patients with inflammatory bowel disease and in no controls without IBD. Seropositivity was strongly associated with the IBD HLA-DRB1*01:03 risk allele. Full study results: https://t.co/C5oIChPFbG

Science behind the Study: Autoantibodies against Cytokines — From Infection to Inflammation https://t.co/Ja8nORGjYr

[EHJ Editor-in-Chief @ehj_ed]

What’s really driving exercise intolerance in HFpEF? It’s more than just the heart. From impaired oxygen delivery to peripheral dysfunction, the multi-organ mechanisms behind a key clinical hallmark of HFpEF are finally coming into focus and they matter for how we treat it. Read more in #EHJ. https://t.co/eP2R8ZvKHG
#HFpEF #cardiotwitter @ESC_Journals @escardio

[Pablo Acevedo @pablocacevedo1]

🧠 Insight clínico

“Corazón pequeño, problema grande”
El tamaño del VI predice mejor la capacidad funcional y el pronóstico que la fracción de eyección.

👉 En HFpEF, el límite es la precarga, no la contractilidad.
https://t.co/t3ZMDtPDoL
#Cardiology #HFpEF
@FH_Verbrugge

[Davide Capodanno @DFCapodanno]

Finally, a sham-controlled CTO PCI trial—and it delivers. ORBITA-CTO: small (n=50), but rigor where it matters—blinding, placebo control, symptom-level data. CTO PCI improves angina beyond placebo, with a clear reduction in episodes and more angina-free days. Not prognosis, not hard endpoints, but real symptom benefit—properly measured. #acc26
https://t.co/UgoJVoX87H

[NEJM @NEJM]

Presented at #ACC26:

In patients with pulmonary embolism, ultrasound-facilitated, catheter-directed fibrinolysis led to a lower risk of a composite of major adverse outcomes than anticoagulation alone. Full HI-PEITHO trial results: https://t.co/itevLNqK0Z

Editorial: Advanced Therapy for Intermediate-Risk Pulmonary Embolism https://t.co/4YIifUjCwH

@ACCinTouch

[Jay Giri @jaygirimd]

🧵 1/ Many are prob confused about what all the debate is about the Keto diet & its relationship to serum lipids as well as potential CV effects of this

I’ll try to break this down below (hopefully fairly)

Disclaimer: I’m not a lipid expert but have great interest in the field

[EJHF Editor-in-Chief @EJHFEiC]

Clinical characteristics and outcomes of cardiomyopathies related to immune-mediated diseases

https://t.co/jK96EjKB4U
@ESC_Journals #EJHF @HanCardiomd @GiuseppeGalati_
@AmrAbdin10

[Sebastiaan Dhont @S_Dhont]

🗞️ HFpEF isn’t about weak contraction but trapped reserve - when stroke volume stalls, heart rate must run free.

A story of 🦒, 🐦 and 🐋.

@Ph_Bertrand

[Omar Hahad @OmarHahad]

„Werden die Blutgerinnsel in der Lunge bei einer akuten
Embolie nicht richtig abgebaut, können sie chronisch werden. Mit der Zeit bilden sich spinnennetzartige Bindegewebsfäden in den Gefäßen“, erklärt Embolie-Spezialist @lukashobohm .

[Yogesh Reddy @yreddyhf]

Echo DD guidelines are consensus based and require testing to determine clinical utility. In this multicenter study with gold standard dx, we show poor sensitivity and accuracy for resting and exercise echo criteria. @JACCJournals

https://t.co/x64Fl4Sh3X

[Cihan Çelik @Celik_Chn]

Wir leisten uns in Europa eines der teuersten Gesundheitssysteme, sind aber bei Prävention Schlusslicht. Auch, weil wir falsche Prioritäten setzen und viele den Schutz vor Gesundheitsgefahren & Präventionsmaßnahmen wie Nichtraucherschutz als Einschränkung von Freiheit betrachten.

[Matthias Nahrendorf @MatthiasNahrend]

Post-MI immunomodulation ❤️‍🔥 are we on our way to a clinical trial?

CD14 Blockade Modulates Macrophage-Mediated Immunological Injury in a Translational Model of Reperfused ST-Segment Elevation Myocardial Infarction | JACC: Basic to Translational Science https://t.co/IujIKd7tWy

[NEJM @NEJM]

Presented at #AHA25:

In a meta-analysis of 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full results: https://t.co/1LiJFFvnm3

@AHAScience

[ECMO_Doc @doc_ecmo]

ECPR in a nursing home resident… only in Germany….

https://t.co/ULkJcJNsQT

[Davide Capodanno @DFCapodanno]

We authored this state-of-the-art review, now published in JACC, to provide an updated, comprehensive overview of post–myocardial infarction inflammatory mechanisms and to critically evaluate the emerging clinical evidence on anti-inflammatory therapies for secondary cardiovascular prevention. https://t.co/cb4VpNHiUy

[Nature Medicine @NatureMedicine]

In a randomized trial of patients with a previous #MyocardialInfarction and with residual #inflammation, a monoclonal antibody targeting the protein LOX-1, thought to contribute to #atherosclerotic plaque progression and #inflammation, reduced soluble LOX-1 and IL-6 levels but did not lead to a significant reduction in #coronary plaque volume.
https://t.co/sGEBdCVJi8

[Harlan Krumholz @hmkyale]

For anyone who has wanted a clear, authoritative summary of inflammation and cardiovascular disease, and where the science is heading, here it is.
The 2025 ACC Scientific Statement on Inflammation and Cardiovascular Disease. @JACCJournals https://t.co/9W4ixNqRTN

[Holger Thiele @thiele_holger]

Fall des Jahres ⁦@AGIKinterv⁩ aus Mainz. LAE bei einer Schwangeren ⁦@KardiologieHH⁩ ⁦@klinki_hh⁩ ⁦@PhilippLurz⁩ ⁦@KP_Kresoja⁩

[Raviele Antonio @drraviele]

WITHDRAW-AF RCT
📌 In👫w/ presumed AF-induced #cardiomyopathy & normalized #LVEF after SR restoration
👉 withdrawal of #HF therapy is not assoc w/ LVEF ⬇️ again in 90% of👫in the following 6-m
#EPeeps #afib #HeartFailure #CardioTwitter #MedTwitter @DrMarthaGulati @JagSinghMD

[Marios Georgakis @MariosGeorgakis]

Most people know that ALS is a deadly disease.

But most don't know that an ALS diagnosis is often missed at early disease stages due to lack of specific biomarkers.

Now, a plasma proteomic signature of 33 proteins (based on Olink Explore) achieved discrimination of >95%!